FDA Gives Accelerated Approval To Amgen’s Drug For Small Cell Lung Cancer Patients
FDA approves Amgen's Imdelltra for treating ES-SCLC, based on response rate and DoR in clinical studies. Approval may depend on further trials.
Myriad Genetics Study Published In JCO Precision Oncology Shows Co’s Prolaris Test Can Predict Benefit Of Hormone Therapy Treatment In Men With Localized Prostate Cancer
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN),
CareDx Presents Findings from The SHORE Study, HeartCare Outperforms dd-cfDNA Alone In Identifying Rejection And Patients Experienced Fewer Biopsies
HeartCare Results Effectively Stratified Patients at Highest Risk for Acute Cellular RejectionCardiologists Performed the Fewest Biopsies After Dual Negative HeartCare Results Compared to Single or Dual Positive
Evoke Pharma Presents Additional GIMOTI Healthcare Utilization Data Focused On Gastroparesis Care Insights In Women At DDW 2024 Conference
Evoke Pharma, Inc.(NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that
Inventiva Receives Recommendation From The 4th Scheduled Data Monitoring Committee Meeting Of The NATiV3 Phase III Clinical Trial With Lanifibranor In Patients With MASH/NASH
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review
Attention Biotech Investors – Stocks To Watch
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences, and Corbus Pharmaceuticals with key 2024 data readouts and trials.
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Johnson & Johnson acquires Proteologix for $850 million, expanding its bispecific antibody portfolio for immune-mediated diseases.
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with mild to moderate adverse events.
Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.
FDA Approves Expanded Use Of Bristol Myers Squibb’s Breyanzi Cancer Cell Therapy For Previously Treated Follicular Lymphoma
FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory follicular lymphoma. Breyanzi is included in NCCN guidelines and shows high response rates and sustained clinical benefits in trials.